Fedratinib is a selective JAK2 inhibitor approved for the treatment of myelofibrosis, where it functions by disrupting the JAK–STAT signaling pathway, a critical regulator of hematopoietic cell proliferation and survival [55–57]. Here, SOAT1 is linked to myelofibrosis.